| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 25,420 | +1,68 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) | - TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG =880 mg/dL (=10 mmol/L) - - Approximately 700,000 people in the EU5 are estimated to have triglyceride... ► Artikel lesen | |
| CSPC PHARMA | 0,901 | 0,00 % | CSPC Pharmaceutical Group Ltd. Announces Rise In Nine Months Bottom Line | ||
| SELLAS LIFE SCIENCES | 16,650 | +1,83 % | Aktie verdreifacht sich: Sellas Life Sciences: Neuer Krebsimpfstoff beflügelt | © Foto: adobe.stock.comDie Aktie von Sellas Life Sciences verzeichnet nach überzeugenden Studiendaten zu einem experimentellen Blutkrebs-Impfstoff einen historischen Kurssprung Enthaltene Werte: US81642T2096Den... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 364,20 | +0,41 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| ACADIA PHARMACEUTICALS | 16,555 | +1,88 % | Oppenheimer senkt Kursziel für Acadia Pharmaceuticals wegen Pipeline-Aussichten | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 3,620 | +1,12 % | Opus Genetics, Inc.: Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 | OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement... ► Artikel lesen | |
| SAVARA | 4,353 | +0,90 % | H.C. Wainwright initiates Savara stock coverage with buy rating | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information | Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM ESTNorthvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company")... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,580 | +4,88 % | Galectin Therapeutics GAAP EPS of -$0.04 beats by $0.01 | ||
| BIODEXA PHARMACEUTICALS | 1,350 | -7,53 % | XFRA NEW INSTRUMENTS AVAILABLE ON 28.10.2026 | The following instruments on XETRA do have their first trading 28.10.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 28.10.2026
Aktien
1 US59564R8640 Biodexa Pharmaceuticals... ► Artikel lesen | |
| CGN MINING | 0,220 | 0,00 % | CGN MINING (01164): RESIGNATION OF JOINT COMPANY SECRETARY | ||
| PHOTOCURE | 3,805 | 0,00 % | Photocure partners with Clinigen on Named Patient Program broadening Access to Hexvix/Cysview (hexaminolevulinate HCl) | OSLO, Norway, Nov. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) announces today that it entered into an agreement with Clinigen, for global supply of Hexvix under a Named Patient Program (NPP)... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,920 | -1,03 % | ARCTICZYMES TECHNOLOGIES: Long-Term Incentive Plan - grant of share options to primary insiders | ||
| NEURIZON THERAPEUTICS | 0,026 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Bell Potter Healthcare Conference Presentation |